Background. Increasing resistance to antibiotics of the pathogens causing acute otitis media (AOM) emphasize the need for effective methods to prevent episodes of otitis media in young children.
INTRODUCTION
Acute otitis media (AOM) is one of the most common diseases in early infancy and childhood. By the ages of 1 and 3 years, 62 and 83% will have experienced at least one episode of AOM, respectively. 1 As many as 5% of all children are considered to be otitis-prone with at least three AOM episodes within 6 months or four or more episodes within 1 year. 2 In view of the long term effects of recurrent episodes of otitis media (OM), rapid emergence of drug resistant bacteria associated with AOM worldwide and huge estimated direct and indirect annual financial costs associated with OM, there is need for an effective vaccination program to prevent OM. [3] [4] [5] [6] [7] [8] Vaccine development has focused on pneumococcal vaccines because Streptococcus pneumoniae is the most common bacterial cause of AOM and communityacquired pneumonia and a leading cause of invasive diseases like meningitis and bacteremia with high case-fatality rates. 9 The preventive effect of both pneumococcal polysaccharide vaccines and pneumococcal conjugate vaccines in AOM has been assessed in several trials. Thus far no systematic review of the current available evidence regarding pneumococcal vaccination for prevention of AOM has been published. In this review we aim to estimate the effectiveness of both pneumococcal polysaccharide and pneumococcal conjugate vaccines in the prevention of AOM in infants and children and to identify subgroups for which the vaccine might in particular be useful. . The search terms used were exploded MeSH headings: bacterial vaccines, vaccination, otitis media and the free text terms: pneumococc* near immuni*, pneumococc* near vaccin*, otitis next media. We also used the bibliographies to identify other published studies and contacted Merck, Sharp & Dohme and Wyeth Lederle Vaccines for information about unpublished studies. All randomized controlled clinical trials on pneumococcal vaccination with prevention of AOM as outcome in children younger than 12 years old and a follow-up period of at least 6 months were included in this systematic review.
Data extraction and outcome measure. Data extraction was performed independently by the first two authors followed by a consensus conference to resolve any differences. Data extraction included: description of participants; description of intervention; description of control condition; total number of children in each study group; total number of AOM episodes; and follow-up period in months. Bacteriologic data on episodes of AOM after vaccination were extracted to establish whether the vaccines had protected against specific serotypes of pneumococci present in the vaccine. The main outcome measure was the total number of AOM episodes during follow-up. Another outcome measure was the number of AOM episodes caused by pneumococcal serotypes present in the vaccine or caused by pneumococcal serotypes not present in the vaccine. First or corresponding authors were contacted to obtain additional information where necessary.
Quality assessment. Study quality was assessed independently by five of the authors using the Jadad criteria consisting of a three item quality scale with a score ranging from zero to five. 10 One point was allocated for randomization, double blinding and description of withdrawals and dropouts; an extra point was added for methods of randomization and blinding that were well-described and adequate. Studies that used a clearly inadequate method of randomization or blinding lost the point allocated. Disagreement was resolved by discussion.
Statistical analyses. Vaccine effect was estimated as a rate ratio defined as: (total AOM episodes pneumococcal vaccination group/number of children pneumococcal vaccination group*follow-up in months)/(total AOM episodes control group/number of children control group*follow-up in months). Overall and age-specific rate ratios were analyzed with log linear Poisson regression. Fixed effects models are presented with allowance for extra Poisson variation to account for heterogeneity when the P value of the test for model fit without extra Poisson variation was Ͻ0.05. 11, 12 Standard errors of estimates multiplied by the square root of deviance divided by degrees of freedom in the classical Poisson regression gave the standard errors in the case of extra Poisson variation. Log linear Poisson regression was undertaken with the Genmod procedure in Statistical Analysis System (SAS Version 6.12). Subgroup analyses were conducted on children who had a history of documented episodes of AOM before study entrance.
Sensitivity analysis was performed once by excluding the study with the lowest methodologic quality score and once by excluding the study in which randomization had failed because of large randomization blocks. Publication bias was assessed by a scatter plot (funnel-plot) of the log rate ratios (x-axis) vs. precision defined as 1/SE (Y-axis) of the eight studies with respect to pneumococcal polysaccharide vaccination.
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RESULTS
Results of the literature search. The Medline search yielded 16 potentially relevant randomized controlled trials.
14 -29 An additional relevant trial was found in the Cochrane Controlled Trial Register and in the Cochrane Acute Respiratory Infections Group trial register. 30, 31 Two studies were excluded because AOM was not an outcome. 14, 30 One citation was excluded because it included an additional analysis of Sloyer 15 but no additional information. The search yielded 3 double citations, leaving 12 trials on the effect of pneumococcal vaccination against AOM in children. Quality assessment of these studies revealed that one study was not a trial; therefore it was excluded. 16 This left 11 trials. Tables 1 and 2 show qualitative and quantitative results of the included trials, respectively. It should be mentioned that 8-to 14-valent polysaccharide vaccines were used in the reviewed studies, because 23-valent polysaccharide vaccine was not yet available.
The quality score of the included studies varied from zero to five (Table 1) . Although Rosen et al. 25 did not mention the use of randomization, the reviewers believe there is no reason to assume that this study was not randomized. According to the guidelines, however, no points were assigned. All the other studies were reported as randomized, but in most of them the method of randomization was not described. 22, 23, 26 -28 In two of the five studies that did report on the method of randomization, this was done inappropriately by sequentially assigning intervention 20 and too large randomization blocks resulting in unequal groups. 24 Except for Makela et al. 20 and Schuller, 23 the studies were double blinded and the method of double blinding was appropriate. The method of double blinding was not described by Sloyer et al. 21 and Eskola et al. 28 Apart from Schuller, 23 Douglas and Miles, 24 Eskola et al. 28 and Dagan et al., 29 no information about the number of withdrawals and dropouts was given in any of the studies.
The funnel-plot ( Fig. 1 ) suggests a lack of publica- Fig. 2) ]. The rate ratio in children younger than 24 months was 0.93 (95% confidence interval, 0.83 to 1.05), whereas the rate ratio in children older than 24 months was 0.78 (95% confidence interval, 0.63 to 0.97). Exclusion of the study with the lowest quality score did not affect the results. 20 In the study on Aboriginal children, randomization errors had resulted in groups of unequal size, and no information on previous episodes of AOM was given. 31 Therefore this study was excluded from further analyses. Pneumococcal polysaccharide vaccination had a moderate effect on the prevention of AOM episodes in children older than 24 months.
Pneumococcal polysaccharide vaccination: effect of previous AOM history. The overall pooled rate ratio in the group of children without any previous documented AOM episodes was 0.92 [95% confidence interval, 0.85 to 0.99 (Table 3 ; Fig. 3) ]. In children younger than 24 months, the rate ratio was 0.94 (95% confidence interval, 0.87 to 1.02); in children older than 24 months the rate ratio was 0.81 (95% confidence interval, 0.68 to 0.98). These results show that, independent of age, pneumococcal polysaccharide vaccination had only a small effect on the prevention of AOM in children without a previous history of AOM.
Subgroup analysis on children with documented AOM episodes before vaccination showed a pooled rate ratio of 0.85 (95% confidence interval, 0.74 to 0.98) in the younger age group vs. 0.74 (95% confidence interval, 0.62 to 0.90) in the older age group. Regardless of age the rate ratio was 0.81 [95% confidence interval, 0.72 to 0.91 (Table 3 ; Fig. 4) ]. Pneumococcal polysaccharide vaccination seemed to prevent AOM effectively, independent of age, in children with documented AOM episodes before vaccination.
Pneumococcal conjugate vaccine. Two studies conducted in healthy Californian and Finnish infants immunized as early as 2 months of age have addressed the effect of 7-valent pneumococcal conjugate vaccination against AOM. 27, 28 A third study addressed the effect of 9-valent pneumococcal conjugate vaccination against acute respiratory infections, including otitis media, in toddlers 12 to 35 months of age, attending day care and receiving vaccination at 12 to 35 months of age. 29 In the Finnish study of healthy infants, 28 a rate ratio of 0.93 (95% confidence interval, 0.86 to 1.00) was calculated with intentionto-treat data. Results of the Israeli trial 29 suggest that 9-valent pneumococcal conjugate vaccination prevents otitis media in toddlers attending day care, with a rate ratio of 0.83 (95% confidence interval, 0.67 to 1.03). Because the California study 27 did not provide any details on follow-up duration, only the results of the Finnish 28 and Israel 29 studies could be pooled, leading to a rate ratio of 0.92 [95% confidence interval, 0.85 to 0.99 (Table 3) ]. As the California and Finnish study had a similar design, both immunizing healthy infants at 2, 4 and 6 months of age and again at 12 to 15 months of age, we compared the vaccine efficacy against recurrent AOM (at least three episodes within 6 months, or at least four episodes within 1 year). According to the intention-to-treat analysis, the risk of recurrent AOM was reduced by 9% (95% confidence interval, 4 to 14%) by pneumococcal conjugate vaccination in the California study and also by 9% (95% confidence interval, 12 to 27%) in the Finnish study.
Efficacy against pneumococcal serotypes. Three studies addressing the effect of pneumococcal polysaccharide vaccination provided detailed information on the number of AOM episodes after vaccination caused by vaccine and nonvaccine pneumococcal serotypes. 20, 21, 26 Regardless of age and previous AOM history, the pooled rate ratio of AOM episodes caused by pneumococcal serotypes present in the polysaccharide vaccine was 0.92 (95% confidence interval, 0.64 to 1.33). The pooled rate ratio of AOM episodes caused by pneumococcal serotypes not present in the polysaccharide vaccine was 0.91 (95% confidence interval, 0.62 to 1.33). These results do not show a clear effect of pneumococcal polysaccharide vaccination in preventing AOM episodes caused by specific pneumococcal serotypes present in the vaccine.
The pneumococcal conjugate vaccine was more effective in preventing the number of AOM episodes caused by pneumococcal serotypes present in the vaccine, with a rate ratio of 0.43 (95% confidence interval, 0.34 to 0.54). 28 However, the rate of AOM episodes caused by 
DISCUSSION
Multivalent pneumococcal polysaccharide vaccine tends to prevent 10% of AOM episodes in young children regardless of age. However, the pooled results of the pneumococcal polysaccharide vaccination trials support the general opinion that the pneumococcal polysaccharide vaccine is at best moderately effective in children older than 24 months and not effective in children younger than 24 months. 9 This conclusion is consistent with the knowledge that the vaccine pneumococcal polysaccharides are T cell-independent antigens that are in general poorly immunogenic before 18 to 36 months of age and fail to induce a memory response.
In contrast conjugated vaccines induce a T celldependent immune response from as early as 2 months of age. Repeated immunizations have been shown to induce IgG immune responses at this early age because of the immunologic memory induced by the conjugate vaccine.
In general pneumococcal conjugate vaccine would significantly prevent 8% of AOM episodes in infants and toddlers. The results of the Israeli study 29 suggest that the pneumococcal conjugate vaccination is moderately effective in toddlers attending day care; vaccination tends to prevent 17% of AOM episodes. The seemingly higher vaccination impact in this specific group of children may be explained by the possible effect of environmental infection pressure with higher rates of respiratory tract infections and acute otitis media, caused by antibiotic-resistant pneumococcal serotypes included in the vaccine.
In children with a previous documented history of AOM, pneumococcal polysaccharide vaccination would significantly prevent 19% of AOM episodes; whereas in children without previous documented AOM, vaccination prevents 8% of AOM episodes. The precise reason why children with recurrent AOM would benefit more from vaccination is unknown. One reason might be that having experienced one episode of AOM predisposes to a higher risk of a second AOM episode, possibly because of changed conditions in the middle ear cavity. Statistically the child with a higher risk for AOM will benefit more from prevention by vaccination. Consequently vaccination could have more impact in children with a history of recurrent AOM. This may even outweigh the fact that children with recurrent respiratory tract infections may be poor responders to some weak immunogenic pneumococcal serotypes included in the vaccine. 32, 33 The pneumococcal conjugate vaccine may overcome poor responses not only at infant age but also in toddlers and older children who failed to respond to the T cell-independent polysaccharide vaccine. 34, 35 With respect to the individual pneumococcal polysaccharides and prevention of AOM by that particular type, no clear distinction was observed between vaccine and nonvaccine serotypes after polysaccharide vaccination. However, a better protective effect against those serotypes with the highest IgG antibody response was observed in the study of Makela et al. 20 Protection against nonvaccine serotypes, however, might be induced by cross-reactive antibodies. This was shown in the Finnish study for serotypes 6A and 19A, after vaccination with the 7-valent pneumococcal conjugate vaccine including serotypes 6B and 19F. 28 In this same trial an increase in AOM episodes caused by nonvaccine pneumococcal serotypes without cross-reactive activity was observed. This indicates that a shift has occurred toward infection by nonvaccine pneumococcal serotypes that may have pathogenic potential and important clinical implications in the long term. 28 For that reason it should be emphasized that the results of further studies on the effect of pneumococcal conjugate vaccination studies in infants and older children are required. Importantly post-implementation studies are indicated because of this potential pathogenic replacement of nonvaccine pneumococcal serotypes, before widespread implementation of the pneumococcal conjugate vaccine for AOM. 29, 36, 37 The validity of the results of this systematic review may be questioned, mainly because of differences of the studies in AOM definition, inclusion criteria of the children, methodologic study quality and publication bias. One important difference in studies is the definition of the clinical outcome of AOM. In 7 of 11 studies, AOM is defined as having one or more acute symptoms of infection (e.g. fever, earache, otorrhea, vomiting and diarrhea) in addition to the presence of fluid in the middle ear as verified by pneumatic otoscopy, tympanometry or myringotomy. 20 -23, 25, 28 Two studies have used parental report to record the frequency of AOM, 24, 38 1 study used computerized data on diagnoses registered by emergency physicians and pediatricians 27 and from 1 study it was unclear which definition was used. 31 Although these differences in AOM diagnosis might explain variability in AOM rate per study, the double blind design of most studies should prevent reporting bias. Consequently we believe that differences in AOM definitions would not invalidate the results of this systematic review. With respect to the inclusion criteria, only Rosen et al. 25 and Black et al. 27 excluded children known to be at risk for (recurrent) AOM or to be likely to show a poor vaccine response because of a known immunodeficiency disorder. Although exclusion of the study of Rosen et al. (1984) in the overall analyses did not influence the results, we cannot predict whether these exclusion criteria will have positively or negatively influenced vaccine efficacy. Overall the quality of the various studies was fairly comparable and excluding the study with the lowest quality score 20 did not influence the overall results. The Jadad method was very sensitive to written information of the published manuscripts. Most studies lost 1 or 2 points, on a 5-point scale, because the method of randomization was not described and/or information about withdrawals and dropouts was missing. Overall the interpretation of the funnelplot suggests a lack of publications on small studies that did not demonstrate any beneficial treatment effect of the pneumococcal polysaccharide vaccine. This may imply that the effect of pneumococcal polysaccharide vaccination on the prevention of AOM is overestimated in this review. However, the plot is only slightly asymmetric and therefore not very convincing. Consequently it can be concluded that bias was insubstantial and that the results of the vaccination effect against AOM described in this systematic review are valid. 39 Despite the limitations pointed out, and from the perspective of evidence-based medicine at this moment, this is the best evidence available. On the basis of this systematic review, we cannot recommend large scale pneumococcal vaccination to prevent otitis media in general. Results of ongoing trials should be awaited before making any recommendations about vaccination of specific high risk (otitis-prone) populations, such as children attending day care or children with recurrent otitis media.
This review is also available in the Cochrane Library (Issue 2, 2002 ). It will be regularly updated with new data and comments.
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FIG. 3. "Forest plot"
showing results from randomized controlled trials on pneumococcal polysaccharide vaccination against otitis media in children without any previous documented AOM episodes. F, rate ratio (RR) for the trials; OO, 95% confidence interval (CI). 
